We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan
Read MoreHide Full Article
AstraZeneca PLC (AZN - Free Report) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grünenthal, a German pharmaceutical company.
Previously, AstraZeneca had licensed the commercial rights of Zomig in the U.S. to Impax Laboratories, Inc. . Impax will now continue to market Zomig in the U.S. along with Grünenthal. Zomig is also indicated for treatment of acute migraine and cluster headache in the EU.
Under the licensing deal, AstraZeneca will receive $200 million upon its completion. The company will also be entitled to receive up to $102 million in future milestone payments. The agreement is expected to be closed in the second quarter of 2017.
AstraZeneca’s shares have outperformed the Zacks classified Large Cap Pharma industry so far this year. The company’s shares have gained 27.7% compared with the industry’s gain of 10.1%.
Significantly in 2016, revenues from Zomig outside Japan were $96 million. The company said, the agreement does not impact the financial guidance for 2017.
Investors must remember that AstraZeneca continues to divest medicines that are outside the main therapy areas in order to redirect investment and resources into the thrust areas of focus. With this objective, the company executed ten transactions that contribute to externalization revenue and completed nine such divestments in 2016.
Per the company’s press release, more than 75 million people worldwide are suffering from migraine. Given that not many drugs have yet been able to offer a solution for migraine, there exists an unmet need for new therapies in this field.
AstraZeneca currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in healthcare sector include VIVUS, Inc. and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) . While VIVUS sports a Zacks Rank #1 (Strong Buy), Regeneron carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’s loss per share estimates narrowed down from 50 cents to 39 cents for 2017 in last 60 days. The company posted positive earnings surprises in all four trailing quarters with average beat of 233.69%.
Regeneron’s earnings per share estimates increased from $10.16-$10.52 for 2017 and from $10.90-$12.10, over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters with average beat of 0.45%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan
AstraZeneca PLC (AZN - Free Report) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grünenthal, a German pharmaceutical company.
Previously, AstraZeneca had licensed the commercial rights of Zomig in the U.S. to Impax Laboratories, Inc. . Impax will now continue to market Zomig in the U.S. along with Grünenthal. Zomig is also indicated for treatment of acute migraine and cluster headache in the EU.
Under the licensing deal, AstraZeneca will receive $200 million upon its completion. The company will also be entitled to receive up to $102 million in future milestone payments. The agreement is expected to be closed in the second quarter of 2017.
AstraZeneca’s shares have outperformed the Zacks classified Large Cap Pharma industry so far this year. The company’s shares have gained 27.7% compared with the industry’s gain of 10.1%.
Significantly in 2016, revenues from Zomig outside Japan were $96 million. The company said, the agreement does not impact the financial guidance for 2017.
Investors must remember that AstraZeneca continues to divest medicines that are outside the main therapy areas in order to redirect investment and resources into the thrust areas of focus. With this objective, the company executed ten transactions that contribute to externalization revenue and completed nine such divestments in 2016.
Per the company’s press release, more than 75 million people worldwide are suffering from migraine. Given that not many drugs have yet been able to offer a solution for migraine, there exists an unmet need for new therapies in this field.
Astrazeneca PLC Price
Astrazeneca PLC Price | Astrazeneca PLC Quote
Zacks Rank & Key Picks
AstraZeneca currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in healthcare sector include VIVUS, Inc. and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) . While VIVUS sports a Zacks Rank #1 (Strong Buy), Regeneron carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’s loss per share estimates narrowed down from 50 cents to 39 cents for 2017 in last 60 days. The company posted positive earnings surprises in all four trailing quarters with average beat of 233.69%.
Regeneron’s earnings per share estimates increased from $10.16-$10.52 for 2017 and from $10.90-$12.10, over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters with average beat of 0.45%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>